Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective
N Villarino1, S A Brown, T Martín-Jiménez
1Department of Microbiology, College of Arts and Sciences, University of Tennessee, Knoxville, TN, USA.
Abstract:
Tulathromycin is approved in the United States for the treatment of respiratory disease in bovine and swine, infectious bovine keratoconjunctivitis associated with Moraxella bovis, and interdigital necrobacillosis in bovine. This macrolide highly concentrates in lung tissue and persists in the intra-airway compartment for a long time after a single administration. It also accumulates in inflammatory cells, including neutrophils and macrophages. This article reviews pharmacokinetic information about tulathromycin in different veterinary species with particular emphasis on the respiratory system.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacodynamic Models: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics: Overview
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...


